The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing…
Articles by Steve Bryson, PhD
Amylyx Pharmaceuticals‘ investigational oral therapy AMX0035 reduces the levels of several biomarkers associated with Alzheimer’s disease, according to…
VY-TAU01, Voyager Therapeutics’s investigational therapy designed to prevent the formation of harmful tau tangles in the brains of people…
Enrollment is now complete in the LIFT-AD clinical trial evaluating Athira Pharma‘s fosgonimeton, an experimental treatment for mild-to-moderate…
NE3107, BioVie Pharma’s experimental oral therapy, was superior to a placebo at improving performance of adults with mild-to-moderate…
Weekly injections of an investigational formulation of the Alzheimer’s disease therapy Leqembi (lecanemab) worked better than the approved…
Treatment for two years with oral ALZ-801 (valiltramiprosate) sustained cognition and lowered levels of disease-related biomarkers in people with…
Vaccine candidate UB-311 is safe, well tolerated, and triggered an antibody response against beta-amyloid in 93% of patients with…
Recruitment has begun for a Phase 2 clinical trial that’s evaluating Cognition Therapeutics’ once daily oral therapeutic candidate Elayta in…
“Encouraging results” were reported in eight Alzheimer’s disease patients with dementia who were treated with COYA 301, an experimental…